Back to News
Market Impact: 0.3
City Therapeutics Prices Upsized $200 Mln IPO At $18/shr
Source: Nasdaq
IPOs & SPACsHealthcare & Biotech
City Therapeutics priced its upsized IPO at $18.00 per share, offering 11 million common shares. The clinical-stage company develops RNA interference therapeutics; the article provides no trading response or further offering details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Yields continue to rattle investors. These sectors are most at risk if rates stay elevated
- After years of U.S. export bans, China plans its own: 40 AI, chip and solar technologies could be restricted
- Anthropic signs first Canada data centre lease as EverWind plans C$10B investment
- CoreWeave, Nscale Put Neocloud Economics in Focus
- MapLight Therapeutics CMO Erin Foff sells $124,068 in stock
- William Blair initiates Revolution stock with outperform on RAS franchise